Henry Schein Dental to be sales agent, exclusive distributor of ARESTIN

MELVILLE, New York--Henry Schein, Inc. has announced that Henry Schein Dental and OraPharma, Inc., have entered into a relationship that will extend the offering of ARESTIN.

Through this agreement, Henry Schein Dental will serve as sales agent and exclusive U.S. distributor of ARESTIN, the first locally administered, time-released antibiotic encapsulated in microspheres that kills the germs that cause periodontal disease or periodontitis.

Henry Schein is a distributor of health-care products and services to office-based practitioners in the combined North American and European markets.

OraPharma is a Johnson Johnson company.

"This is an exciting alliance that provides Henry Schein Dental with a significant offering in an important new market for our Company," said Tim Sullivan, president of Henry Schein Dental. "Our goal is to provide 'everything dental' to our customers, and the addition of ARESTIN to our offering certainly furthers that mission. ARESTIN provides unique benefits for treating a condition that affects millions of Americans. We see great potential for the adoption of ARESTIN by our U.S. Dental customers, in addition to periodontists, and we look forward to collaborating with OraPharma's field representatives as we grow ARESTIN's market share in this country."

Currently, more than one in three Americans older than age 30 has some form of periodontal disease, according to the American Academy of Periodontology. Research shows that untreated periodontal infections may contribute to systemic health problems, including cardiovascular disease.

In addition, according to the Academy of General Dentistry, every $1 spent on preventative oral care results in an $8-$10 savings in subsequent restorative services.

For more information, visit the Henry Schein Web site at Henry Schein.

To read more about Henry Schein, go to Henry Schein.

To comment on this topic, go to PennWell Dental Community site.

Did You Like this Article? Get All the Dental Industry News Delivered to Your Inbox

Subscribe to an email newsletter today at no cost and receive the latest news and information.

Related Articles

Carestream Dental and AAP Foundation announce recipient of $10k teaching award

DentistryIQ Editors 10/21/2014

University of Minnesota professor Georgios Kotsakis, DDS, honored

Livionex releases results of dental gel study


Livionex, Inc., which is based in Los Gatos, Calif., released the results of a double blind clinical trial study on reduction of plaque, gingivitis, and gum bleeding.

More news on the oral-systemic link


Maria Perno Goldie, RDH, MS, shares the latest information in research conducted between the link between oral disease and systemic disease.

Oral health worldwide


While oral diseases are common, they often do not receive due consideration, especially among third world countries. Maria Perno Goldie, RDH, MS, takes a look at a recently released report from the World Dental Federation that highlights the key impediments to achieving universal health. The report suggests that oral health is an essential part of general health and is vital to the overall welfare of people.

Stay Connected

Subscribe to Dentistty IQ's Newsletters

1421 S. Sheridan Road
Tulsa, Oklahoma 74112
PH: 800.331.4633